Monoclonal Antibodies (mAbs) have become a major class of biopharmaceutics for the treatment of major human diseases including cancers and autoimmune diseases. Consequently, the market for mAbs is the fastest-growing sector of the biopharmaceutical industry. Cross-institutional and cross-country collaboration is increasingly important in the R&D (research and development) of therapeutic mAbs. We analyzed collaboration patterns by capturing collaborative relationships in mAb R&D. To this end, the network analysis, a promising method for defining and assessing complex collaborative relationships as shown previously by other investigators, has been employed. More specifically, our study aims 1) to visualize the overall institutional collaboration network; 2) to identify the key firms and the behavioral characteristics expressed in the network; 3) to investigate special collaboration patterns among the firms in the network; and 4) to detect the evolving patterns of R&D collaboration from a country-based perspective and understand the changing positions of specific countries throughout the development period. The results of our analysis may help the stakeholders of mAb R&D to make decisions in seeking collaboration partners.